Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.44 |
| ▸ | CDK4 | P11802 | 4/20 | 0.44 |
| ▸ | CCND1 | P24385 | 4/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.44 |
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | PRKACA | P17612 | 3/20 | 0.44 |
| ▸ | PRKACG | P22612 | 3/20 | 0.44 |
| ▸ | PRKACB | P22694 | 3/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | PRKCB | P05771 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCH | P24723 | 1/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.42 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6982735 | 0.79 | CCNT1 (0.41) | PIM1CCNT1CDK9CCNE2CDK4 | |
| SCHEMBL7013228 | 0.78 | PIM1 (0.42) | PIM1CCNT1CDK9CCNE2CDK4 | |
| SCHEMBL7014052 | 0.76 | CCNT1 (0.41) | PIM1CCNT1CDK9CDK2PRKACA | |
| SCHEMBL7005539 | 0.75 | CDK4 (0.55) | PIM1CCNT1CDK9CCNE2CDK4 | |
| SCHEMBL7831573 | 0.71 | SIRT2 (0.59) | PIM1CCNT1CDK9CCNE2CDK4 | |
| SCHEMBL3337275 | 0.66 | CHRM2 (0.49) | — | |
| 3-Formylindole SCHEMBL16402731 | 0.66 | IMPDH2 (0.51) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL6984020 | 0.65 | CDK4 (0.48) | PIM1CCNT1CDK9CCNE2CDK4 | |
| SCHEMBL5828402 | 0.65 | PIM1 (0.48) | PIM1CCNT1CDK9CCNE2CDK4 | |
| SCHEMBL21561758 | 0.65 | L3MBTL1 (0.61) | PIM1MARK3MAP4K2CAMK2BPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134886-A1 | Pharmaceutically active compounds | ASTRAZENECA AB, A SWEDISH CORPORATION | 2003-07-17 | — | — | US | disclosed |
| EP-1042317-B1 | Indole derivatives as PKC-inhiboitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| US-6492409-B1 | SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| US-6337342-B1 | ARYLIMIDAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
| EP-1042317-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032483-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134886-A1 | Pharmaceutically active compounds | HTR3C, HTR6, CNR1 | PIM1 2352/4885CCNT1 354/4885CDK9 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.